NYLIM
ABUS icon

New York Life Investment Management’s Arbutus Biopharma ABUS Stock Holding History

New York Life Investment Management’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-9,934
Closed -$60K – 55
2015
Q3 		$60K Sell
9,934
-10,357
-51% -$91.8K 0.01% 242
2015
Q2 		$241K Buy
+20,291
New +$309K 0.03% 192

Other funds holding ABUS

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
AWG
Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

New York Life Investment Management's ABUS Position: Q4 2015 in Review

New York Life Investment Management sold out of Arbutus Biopharma (ABUS) in Q4 2015, closing a stake of 9,934 shares — an estimated $60K sold.

New York Life Investment Management first reported a position in ABUS in Q2 2015 and held it in 2 quarters. The position peaked at $241K in Q2 2015. 51 funds tracked by Wall St. Rank hold ABUS as of Q4 2015.

  • New York Life Investment Management reported no remaining Arbutus Biopharma position as of Q4 2015 after selling out during the quarter.
  • New York Life Investment Management sold 9,934 Arbutus Biopharma shares in Q4 2015, an estimated $60K.
  • New York Life Investment Management first reported a position in Arbutus Biopharma in Q2 2015 and held it in 2 quarters.
  • New York Life Investment Management's Arbutus Biopharma position peaked at $241K in Q2 2015.
  • 51 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q4 2015.

Based on New York Life Investment Management's 13F filing for Q4 2015, filed 16 Feb 2016.